Researchers at several institutions collaborated to develop the first computational model that predicts prognosis for patients newly diagnosed with multiple myeloma based on tumor genomics and treatments.
The prediction model for individualized risk in newly diagnosed multiple myeloma (IRMMa) uses artificial intelligence (AI) strategies and datasets of newly diagnosed multiple myeloma cases to generate personalized prognoses for individual patients.
The model is the result of collaborative efforts between investigators at Sylvester Comprehensive Cancer Center at University of Miami Miller
